Patents Assigned to Chr. Hansen HMO GmbH
  • Publication number: 20220389468
    Abstract: The present invention relates to the use of one or more glycosidases in the process for the production and/or purification of a produced desired oligosaccharide. The process is preferably a microbial fermentation process using a host microorganism, which may also comprise nucleic acids expressing sugar catabolic pathway proteins suitable for the degradation of saccharides otherwise hindering the purification of the desired oligosaccharide.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 8, 2022
    Applicant: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Publication number: 20220369677
    Abstract: Disclosed is a cereal composition which can be prepared instantly with the addition of a liquid, containing at least one human milk oligosaccharide (HMO), and other components which are necessary for the healthy growth and development of a young 5 individual.
    Type: Application
    Filed: September 19, 2019
    Publication date: November 24, 2022
    Applicant: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Publication number: 20220290198
    Abstract: Disclosed are non-sporulating Bacillus cells for the production of a sialylated oligosaccharide wherein said Bacillus cell has been genetically engineered to possess a lactose permease, a CMP-NeuNAc biosynthesis pathway and a sialyltransferase, as well as a method for producing a sialylated oligosaccharide using said Bacillus cell.
    Type: Application
    Filed: August 10, 2020
    Publication date: September 15, 2022
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Stefanie Habersetzer
  • Patent number: 11427845
    Abstract: The present invention relates to the use of one or more glycosidases in the process for the production and/or purification of a produced desired oligosaccharide. The process is preferably a microbial fermentation process using a host microorganism, which may also comprise nucleic acids expressing sugar catabolic pathway proteins suitable for the degradation of saccharides otherwise hindering the purification of the desired oligosaccharide.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: August 30, 2022
    Assignee: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Patent number: 11390855
    Abstract: A method for making a genetically modified cell having the ability to produce fucosylated compounds comprising the steps of: transforming the cell to express a fucose kinase, transforming the cell to express a fucose-1-phosphate guanylyltransferase, transforming the cell to express a fucosyltransferase.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: July 19, 2022
    Assignee: Chr. Hansen HMO GmbH
    Inventors: Eric Hüfner, Julia Parkot, Stefan Jennewein